Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
CRNX Crinetics Pharmaceuticals, Inc. monthly Stock Chart
CRNX [NASD]
Crinetics Pharmaceuticals, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-2.09 Insider Own0.10% Shs Outstand26.53M Perf Week-10.60%
Market Cap371.42M Forward P/E- EPS next Y-3.03 Insider Trans-68.57% Shs Float20.61M Perf Month-31.74%
Income-50.40M PEG- EPS next Q-0.63 Inst Own97.90% Short Float7.50% Perf Quarter-44.88%
Sales1.20M P/S309.52 EPS this Y-86.10% Inst Trans-2.12% Short Ratio23.13 Perf Half Y-12.50%
Book/sh4.83 P/B2.90 EPS next Y-9.00% ROA-33.90% Target Price36.60 Perf Year-39.71%
Cash/sh4.46 P/C3.14 EPS next 5Y- ROE-37.30% 52W Range10.63 - 28.81 Perf YTD-44.20%
Dividend- P/FCF- EPS past 5Y- ROI-46.00% 52W High-51.40% Beta-
Dividend %- Quick Ratio14.80 Sales past 5Y- Gross Margin- 52W Low31.70% ATR1.97
Employees68 Current Ratio14.80 Sales Q/Q-62.50% Oper. Margin- RSI (14)42.51 Volatility10.98% 15.68%
OptionableNo Debt/Eq0.00 EPS Q/Q-74.20% Profit Margin- Rel Volume0.85 Prev Close13.48
ShortableYes LT Debt/Eq0.00 EarningsMar 18 AMC Payout- Avg Volume66.83K Price14.00
Recom2.00 SMA20-5.27% SMA50-26.87% SMA200-29.35% Volume56,476 Change3.86%
Dec-23-19Initiated ROTH Capital Buy $37
Feb-14-19Initiated H.C. Wainwright Buy $35
Aug-13-18Initiated Piper Jaffray Overweight $40
Aug-13-18Initiated Leerink Partners Outperform $43
Aug-13-18Initiated JP Morgan Neutral $29
Mar-09-20 04:10PM  Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update GlobeNewswire
Mar-04-20 12:30PM  Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for Zacks
Feb-19-20 07:30AM  Crinetics Pharmaceuticals to Participate in SVB Leerink Global Healthcare Conference GlobeNewswire
Jan-28-20 07:11AM  Those Who Purchased Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares A Year Ago Have A 11% Loss To Show For It Simply Wall St.
Jan-08-20 07:30AM  Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference GlobeNewswire +5.61%
Dec-14-19 08:42PM  Hedge Funds Have Never Been This Bullish On Crinetics Pharmaceuticals, Inc. (CRNX) Insider Monkey
Nov-26-19 04:05PM  Crinetics Pharmaceuticals to Participate in the Piper Jaffray Healthcare Conference GlobeNewswire
Nov-12-19 06:15PM  Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:04PM  Crinetics Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Nov-05-19 10:31AM  Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q3 Earnings Expected to Decline Zacks
Oct-30-19 10:57AM  Hedge Funds Have Never Been This Bullish On Crinetics Pharmaceuticals, Inc. (CRNX) Insider Monkey
Oct-28-19 11:31AM  We're Not Very Worried About Crinetics Pharmaceuticals's (NASDAQ:CRNX) Cash Burn Rate Simply Wall St.
Sep-25-19 07:30AM  Crinetics Pharmaceuticals to Participate in Cantor Global Healthcare Conference GlobeNewswire +6.32%
Sep-12-19 08:40AM  What Makes Crinetics Pharmaceuticals (CRNX) a Strong Sell? Zacks
Sep-03-19 04:05PM  Crinetics Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference GlobeNewswire
Aug-13-19 06:15PM  Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:14PM  Crinetics Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Jul-30-19 02:35PM  If You Had Bought Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock A Year Ago, You'd Be Sitting On A 14% Loss, Today Simply Wall St.
Jul-29-19 07:30AM  Crinetics Pharmaceuticals to Receive Final Award of SBIR Grant from NIH for Congenital Hyperinsulinism GlobeNewswire -5.72%
Jul-16-19 09:05AM  Crinetics Pharmaceuticals Appoints Stephanie Okey to Board of Directors GlobeNewswire
May-21-19 07:30AM  Crinetics Pharmaceuticals Initiates Phase 1 Study of CRN01941 for the Treatment of Neuroendocrine Tumors GlobeNewswire
May-13-19 04:11PM  Crinetics Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
May-07-19 12:54PM  Heres What Hedge Funds Think About Crinetics Pharmaceuticals, Inc. (CRNX) Insider Monkey -5.67%
Mar-19-19 07:30AM  Crinetics Pharmaceuticals Doses First Patients in Phase 2 Clinical Trials of CRN00808 for Acromegaly GlobeNewswire
Mar-18-19 07:30AM  Crinetics Pharmaceuticals Appoints Gina Ford, RPh, MBA, as Vice President, Corporate Strategy and Commercial Planning GlobeNewswire
Mar-14-19 04:27PM  Crinetics Pharmaceuticals Announces Upcoming Presentations at ENDO2019 GlobeNewswire
Mar-13-19 04:05PM  Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update GlobeNewswire
Feb-21-19 07:30AM  Crinetics Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference GlobeNewswire -6.51%
Jan-16-19 10:16AM  Top 5 Small-Cap Winners And Losers, Week Of Jan. 7 Benzinga
Jan-08-19 12:50PM  At biotech's big event, a chance for execs to shape LGBTQ diversity on boards American City Business Journals
Jan-02-19 04:05PM  Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference GlobeNewswire
Nov-21-18 08:20AM  New Research Coverage Highlights Chuy's, Viveve Medical, ClearSign Combustion, WhiteHorse Finance, Crinetics Pharmaceuticals, and Boston Omaha Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire +9.88%
Nov-20-18 07:30AM  Crinetics Pharmaceuticals to Participate in Piper Jaffray 30th Annual Healthcare Conference GlobeNewswire
Nov-13-18 04:05PM  Crinetics Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire +10.85%
Sep-26-18 04:05PM  Crinetics Pharmaceuticals to Present at Leerink Partners Roundtable Series: Rare Disease & Oncology GlobeNewswire
Aug-30-18 04:07PM  Crinetics Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Jul-20-18 04:05PM  Crinetics Pharmaceuticals Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares GlobeNewswire
Jul-19-18 08:00AM  Todays Research Reports on Stocks to Watch: CTI BioPharma and Crinetics Pharmaceuticals ACCESSWIRE -7.55%
Jul-18-18 11:37AM  Crinetics Pharmaceuticals stock surges 24% in trading debut MarketWatch
07:27AM  Crinetics Pharmaceuticals prices IPO at $17 a share MarketWatch
Jul-17-18 06:55PM  Crinetics Pharmaceuticals Announces Pricing of Initial Public Offering GlobeNewswire
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and adrenocorticotrophic hormone antagonist for the treatment of cushing's diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vivo Capital VIII, LLC10% OwnerMar 09Sale19.5052810,296168,165Mar 11 05:12 PM
Vivo Capital VIII, LLC10% OwnerFeb 10Sale21.407,555161,677168,298Feb 11 08:00 PM
Vivo Capital VIII, LLC10% OwnerFeb 07Sale22.005,905129,910174,202Feb 11 08:00 PM
Vivo Capital VIII, LLC10% OwnerFeb 04Sale22.8013,460306,888178,816Feb 06 07:22 PM
Vivo Capital VIII, LLC10% OwnerJan 31Sale21.705,400117,180189,335Jan 31 08:00 PM
Vivo Capital VIII, LLC10% OwnerJan 30Sale22.107,600167,960193,555Jan 31 08:00 PM
Vivo Capital VIII, LLC10% OwnerJan 29Sale22.2013,920309,024199,495Jan 31 08:00 PM
Fust Matthew KDirectorDec 16Option Exercise1.913,5006,68516,036Dec 18 06:32 PM
Fust Matthew KDirectorDec 16Sale22.503,50078,75012,536Dec 18 06:32 PM
open in yahoo | open in reuters | open in google